Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives $38.00 Average Target Price from Analysts

Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) have been given an average rating of “Moderate Buy” by the five brokerages that are currently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $38.00.

INO has been the topic of several research reports. Royal Bank of Canada decreased their target price on Inovio Pharmaceuticals from $7.00 to $6.00 and set a “sector perform” rating on the stock in a research note on Friday, November 15th. Oppenheimer reduced their price target on shares of Inovio Pharmaceuticals from $33.00 to $15.00 and set an “outperform” rating on the stock in a research report on Monday, November 18th. Finally, HC Wainwright dropped their price objective on shares of Inovio Pharmaceuticals from $12.00 to $5.00 and set a “neutral” rating for the company in a report on Monday, November 18th.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp acquired a new position in Inovio Pharmaceuticals in the second quarter valued at $661,000. Signature Estate & Investment Advisors LLC purchased a new stake in Inovio Pharmaceuticals during the 2nd quarter valued at approximately $88,000. Rhumbline Advisers lifted its position in Inovio Pharmaceuticals by 5,943.0% during the 2nd quarter. Rhumbline Advisers now owns 38,494 shares of the biopharmaceutical company’s stock worth $311,000 after acquiring an additional 37,857 shares during the period. American Century Companies Inc. grew its stake in shares of Inovio Pharmaceuticals by 62.2% in the 2nd quarter. American Century Companies Inc. now owns 31,565 shares of the biopharmaceutical company’s stock valued at $255,000 after purchasing an additional 12,100 shares during the last quarter. Finally, Cornercap Investment Counsel Inc. acquired a new position in shares of Inovio Pharmaceuticals in the second quarter valued at approximately $184,000. Hedge funds and other institutional investors own 26.79% of the company’s stock.

Inovio Pharmaceuticals Stock Performance

NASDAQ:INO opened at $2.32 on Thursday. Inovio Pharmaceuticals has a 52 week low of $2.14 and a 52 week high of $14.75. The stock’s fifty day moving average is $4.89 and its two-hundred day moving average is $7.13.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.